anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1,261,316. Denture soak composition. COLGATE-PALMOLIVE CO. 11 May, 1970 [29 May, 1969], No. 22570/70. Heading C5D. A neutral denture soak composition comprises an oxidant, a carbonate or bicarbonate, an organic acid and an acid anhydride, these four ingredients all being water-soluble solids. The composition may also contain a surface active agent and a dye which is decolorized by oxidation. In examples the oxidant is a mixture of potassium persulphate and sodium perborate; the carbonate or bicarbonate is sodium bicarbonate, sometimes with magnesium carbonate added; the acid is citric acid or malic acid; the anhydride is succinic anhydride, boric anhydride or maleic anhydride; the surface active agent is sodium dodecyl benzene sulphonate or sodium methylnaphthalene sulphonate with an alkylphenoxypoly(ethyleneoxy)ethanol added and the dye is Acid Red No. 14. The composition also includes flavour oils. The composition may be used as powder or tablets. The sodium dodecyl benzene sulphonate also acts as a lubricant when the composition is tableted.
[GB1261316A]
This is a 6-month program that consists of monthly nutrition and physical activity education sessions (2 hours per session) and includes interactive hands-on activities to help you gain knowledge and skills to make positive lifestyle choices. It is a pilot study to test the effectiveness of this type of health-care program in individuals with prediabetes.
The group distribution of the patients was made using the Random Allocation Software (Version 2.0.0) program and the patients were divided into two groups: the study group and the control group.

The patients were visited by the researcher in their rooms on the morning of the day they were scheduled for surgery, and the purpose of the study was explained to the patients. Verbal and written consent was obtained from those who agreed to participate in the study, and it was explained to the patients that they would be visited again at their bedsides the day after surgery.

The Visual Pain Scale was created to assess the severity of pain. A score of '0' at the left end of the line indicates no pain, and a score of '10' at the right end indicates unbearable pain. In this study, patients were asked to mark the severity of the pain they were experiencing on a scale. The research nurse visited the patient in the service rooms before they were transferred to the operating room to make the first assessment in the study group, and the purpose of the study was explained to the patient. Patient introduction form, pedometer and mobilization motivation card were introduced to the patient. The patient was informed that they would be visited at 10:00 a.m. on the first day after the surgery to mobilize the patient. On the morning of the first day after surgery, the patient's pain status was determined with the Visual Pain Scale. The patient's vital signs were checked and the pedometer was placed on the lumbar region. The patient was mobilized according to the mobilization stage. The number of steps after the first mobilization was recorded on the mobilization motivation card and the card was hung at the bedside. The researcher nurse was informed that he would be visited again in 1 hour and these stages were repeated 3 times.

In the control group, the first evaluation was made by the researcher nurse. Patient introduction form, pedometer were introduced to the patient. On the morning of the first day after surgery, the patient's pain status was determined with the Visual Pain Scale. The patient's vital signs were checked and the pedometer was placed on the lumbar region. The patient was mobilized according to the mobilization stage. The number of steps after the first mobilization was recorded on the mobilization motivation card but was not given to the patient. The researcher nurse informed that he would be visited again in 1 hour and these stages were repeated 3 times.
<P>PROBLEM TO BE SOLVED: To provide a new lipid-nucleic acid particle complex useful for in vitro or in vivo gene transfer.  <P>SOLUTION: The particles can be formed by using a detergent dialysis method using an organic solvent. Upon removal of a solubilizing component (i.e. a detergent or an organic solvent), the lipid-nucleic acid complex forms particles wherein the nucleic acid is serum-stable and is protected from degradation. The particles thus formed have access to extravascular sites and target cell populations and are suitable for the therapeutic delivery of nucleic acids.  <P>COPYRIGHT: (C)2009,JPO&INPIT
In vitro studies have shown that rifaximin did not inhibit cytochrome P450 isoenzymes 1A2, 2A6, 2B6, 2C9, 2C19, 2D6, 2E1 and CYP3A4 at concentrations ranging from 2 to 200 ng/mL [see Clinical Pharmacology (12.3)]. Rifaximin is not expected to inhibit these enzymes in clinical use.

An in vitro study has suggested that rifaximin induces CYP3A4 [see Clinical Pharmacology (12.3)]. However, in patients with normal liver function, rifaximin at the recommended dosing regimen is not expected to induce CYP3A4. It is unknown whether rifaximin can have a significant effect on the pharmacokinetics of concomitant CYP3A4 substrates in patients with reduced liver function who have elevated rifaximin concentrations.

An in vitro study suggested that rifaximin is a substrate of P-glycoprotein. It is unknown whether concomitant drugs that inhibit P-glycoprotein can increase the systemic exposure of rifaximin [see Clinical Pharmacology (12.3)].
This group included 92 non dehydrated patients which were assigned to received oral rehydration solution and racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned and ambulatory (in home) bases.
The invention relates to application of shizandra extract in antidepressant drugs. The invention provides use of the shizandra extract in the antidepressant drugs. The shizandra extract can be used as medicine for preventing or curing the depressive illness. The shizandra extract is pharmaceutical preparation which takes schisandrin, schisantherin, deoxyschizandrin, schisandrin B and so on as active ingredients. The preparation formulations which can be prepared by the shizandra extract are tablets, capsules, solution, suspension, injection or dropping liquid and so on. The shizandra extract is characterized by low toxicity and does not have the defects of calmness, telangiectasia ataxia, epilepsy induction and so on of antidepressants.
PURPOSE: A composition containing eel extract is provided to suppress COX-2 dependent prostaglandin D2(PGD2) generation and to prevent and treat inflammatory or allergic diseases. CONSTITUTION: A composition for preventing or treating inflammatory diseases contains eel extract as an active ingredient. The extract is prepared from eel skin, bone, intestine, or muscle using ethanol, hexane, ethyl acetate, butanol, or water. The extract is an eel hexane fraction prepared by extracting eel with ethanol, dissolving the extract with water, and extracting with hexane. The composition is a functional food or pharmaceutical product. [Reference numerals] (AA) Eel head; (BB) Eel muscle; (CC) Eel skin; (DD) Eel bone and intestine; (EE) Whole eel
Perindopril

In animals, doses of perindopril up to 2,500 mg/kg in mice, 3,000 mg/kg in rats and 1,600 mg/kg in dogs were non-lethal. Past experiences were scant but suggested that overdosage with other ACE inhibitors was also fairly well tolerated by humans. The most likely manifestation is hypotension, and treatment should be symptomatic and supportive. Therapy with the ACE inhibitor should be discontinued, and the patient should be observed. Dehydration, electrolyte imbalance and hypotension should be treated by established procedures.

Among the reported cases of perindopril overdosage, patients who were known to have ingested a dose of 80 mg to 120 mg required assisted ventilation and circulatory support. One additional patient developed hypothermia, circulatory arrest and died following ingestion of up to 180 mg of perindopril. The intervention for perindopril overdose may require vigorous support.

Laboratory determinations of serum levels of perindopril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of perindopril overdose. No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of perindopril and its metabolites.

Angiotensin II could presumably serve as a specific antagonist-antidote in the settling of perindopril overdose, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of perindopril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat perindopril overdose by infusion of normal saline solution.

Amlodipine

Overdosage might be expected to cause excessive peripheral vasodilation with marked hypotension and possibly a reflex tachycardia. In humans, experience with intentional overdosage of amlodipine is limited.

Single oral doses of amlodipine maleate equivalent to 40 mg amlodipine/kg and 100 mg amlodipine/kg in mice and rats, respectively, caused deaths. Single oral amlodipine maleate doses equivalent to 4 or more mg amlodipine/kg or higher in dogs (11 or more times the maximum recommended human dose on a mg/m2 basis) caused a marked peripheral vasodilation and hypotension.

If massive overdose should occur, initiate active cardiac and respiratory monitoring. Frequent blood pressure measurements are essential. Should hypotension occur, provide cardiovascular support including elevation of the extremities and the judicious administration of fluids. If hypotension remains unresponsive to these conservative measures, consider administration of vasopressors (such as phenylephrine) with attention to circulating volume and urine output. As amlodipine is highly protein bound, hemodialysis is not likely to be of benefit.
Psychological symptoms and emotional distress, including anxiety, depression, and posttraumatic stress, are common problems among patients discharged from the intensive care unit (ICU). The presence of psychological distress is associated with poor medical adherence, slower recovery, and reduced quality of life in this patient population. There is a lack of research on evidence-based interventions to address mental health symptoms in ICU patients post-hospitalization. Researchers have recently highlighted the potential utility of peer support/group interventions in the post-ICU recovery process; however, they have yet to be widely tested in interventional trials, and their feasibility and acceptability in the post-ICU population have yet to be demonstrated in a research study. Thus, the purpose of this study is to adapt and deliver a 6-session group-based psychological intervention for post-ICU patients in a single-arm, non-randomized interventional study. Patients' symptoms will be assessed at baseline, post-intervention, and 3-month follow-up. The primary aim of the study is to assess the feasibility and acceptability of the group intervention in the post-ICU patient population. Secondarily, changes in patients' emotional distress will be examined to assess for the impact of the intervention on patients' symptoms.
Histopathological scoring can be based on the areas of certain types of cells or the expression of genotypic or phenotypic characteristics of those cells, as identified by a biological assay. Automating a scoring process with an image analysis algorithm includes correctly delineating the areas of interest, a process known as segmentation. The present systems and methods accomplish this segmentation using a generative adversarial network trained to generate masks covering each area of interest. The invention can perform both segmentation and classification by using a separate image band for each class. A scoring algorithm may utilize the classifications of, for example, a tumor area and an area of immune cell staining by interpreting the separate image bands of each area. Classification problems with more bands would use images with the equivalent number of bands. There is no limit to the number of bands an image can encode for each pixel.
BACKGROUND: Previous studies have shown that lifestyle/environmental factors could accelerate the development of age-related hearing loss (ARHL). However, there has not yet been a study investigating the joint association among genetics, lifestyle/environmental factors, and adherence to healthy lifestyle for risk of ARHL. We aimed to assess the association between ARHL genetic variants, lifestyle/environmental factors, and adherence to healthy lifestyle as pertains to risk of ARHL.
METHODS: This case-control study included 376,464 European individuals aged 40 to 69 years, enrolled between 2006 and 2010 in the UK Biobank (UKBB). As a replication set, we also included a total of 26,523 individuals considered of European ancestry and 9834 individuals considered of African-American ancestry through the Penn Medicine Biobank (PMBB). The polygenic risk score (PRS) for ARHL was derived from a sensorineural hearing loss genome-wide association study from the FinnGen Consortium and categorized as low, intermediate, high, and very high. We selected lifestyle/environmental factors that have been previously studied in association with hearing loss. A composite healthy lifestyle score was determined using seven selected lifestyle behaviors and one environmental factor.
RESULTS: Of the 376,464 participants, 87,066 (23.1%) cases belonged to the ARHL group, and 289,398 (76.9%) individuals comprised the control group in the UKBB. A very high PRS for ARHL had a 49% higher risk of ARHL than those with low PRS (adjusted OR, 1.49; 95% CI, 1.36-1.62; P < .001), which was replicated in the PMBB cohort. A very poor lifestyle was also associated with risk of ARHL (adjusted OR, 3.03; 95% CI, 2.75-3.35; P < .001). These risk factors showed joint effects with the risk of ARHL. Conversely, adherence to healthy lifestyle in relation to hearing mostly attenuated the risk of ARHL even in individuals with very high PRS (adjusted OR, 0.21; 95% CI, 0.09-0.52; P < .001).
CONCLUSIONS: Our findings of this study demonstrated a significant joint association between genetic and lifestyle factors regarding ARHL. In addition, our analysis suggested that lifestyle adherence in individuals with high genetic risk could reduce the risk of ARHL.
Provided are an antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. Also provided is the use of the antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody in the prevention and treatment of tumors.Provided are an antibody that binds to the PD-L1 protein or CD137 protein, an antigen-binding fragment or a variant thereof, as well as a bispecific antibody that can bind to both the PD-L1 protein and the CD137 protein. The bispecific antibody has a strong ability to specifically recognize the PD-L1 protein and the CD137 protein, and can enhance T-cell activity. Also provided is the use of the antibody or the antigen-binding fragment or the variant thereof and the bispecific antibody in the prevention and treatment of tumors. The present invention relates to the field of pharmaceutical synthesis, in particular to a method for preparing a hexahydrofuro-furanol derivative, an intermediate thereof and a preparation method therefor. The preparation method comprises steps of a halogenation reaction, an acylation reaction, an enzymatic reduction reaction, a reaction with amine compounds, and a reductive cyclization reaction, (A1, A2, B, Cp1, C<sub>L</sub>, Cf) wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are hydrogen or a hydroxyl protection group; and R<sub>4</sub> and R<sub>5</sub> are the same or different phenyls, alkyls or substituted phenyls. During the preparation process for the hexahydrofuro-furanol derivative, an enzymatic method is used to construct chirality, and by using such a technical means, products with very high optical purity can be prepared. The preparation method can produce and prepare a key intermediate, (3R, 3aS, 6aR)-hexahydrofuro[2, 3-b]-3-ol, of Darunavir, and is a very economic method suitable for industrial production.
The present invention relates to potassium alginate as a novel pharmaceutical excipient and compositions and healthcare foods thereof. Potassium alginate can be used to prepare chemical drug-containing tablets and granules and also to prepare pills, tablets, granules and capsules of Chinese traditional medicines. Instead of sodium alginate, a current used excipient with potassium alginate, the actions of K+-increasing and Na+-removing can be effective for human body. In addition to excipient, potassium alginate is used as a novel antihypertensive agent, which is also referred as “Na+-removing agent in digestive tract”. Thus, the novel antihypertensive and antihyperlipidemic compositions and healthcare products can be obtained by combining potassium alginate with various pharmaceuticals, Chinese traditional medicines and natural foods. Potent, rapid and long duration of action as well as low toxicity and dosage are provided with said compositions and healthcare products.
OBJECTIVES: I. Define the toxicity and determine the maximum tolerated dose of iodine I 131 humanized monoclonal antibody A33 (131I-huAb A33) in patients with advanced colorectal cancer. II. Describe pharmacokinetics and biodistribution of 131I-huAb A33 by external imaging in these patients. III. Determine the effect of human antihuman antibody response on pharmacokinetics and targeting of 131I-huAb A33 in this patient population. IV. Determine whether the dose planning methodology used here can adequately and safely be applied to routine radioimmunotherapy planning.

OUTLINE: Patients receive iodine I 131 humanized monoclonal antibody A33 (131I-huAb A33) by IV infusion over 20 minutes every 6-8 days for up to 8 weeks (depending on dosage). Patients receive a minimum of 6 weeks of treatments. In the absence of disease progression or unacceptable toxicity, patients are retreated no sooner than 6 weeks after the previous course. Cohorts of 3-6 patients receive escalating doses of 131I-huAb A33 to determine the maximum tolerated dose (MTD). The MTD is defined as the highest dose at which no more than 2 of 6 patients experience dose limiting toxicity. Patients are followed for 6 weeks after the last treatment.

PROJECTED ACCRUAL: There will be 3-24 patients accrued into this study over 16 months.
The objective of this 6 month, interventional, open label prospective pilot study is to evaluate the effects of a cadexomer iodine gel on the prevention of recurrent keloid formation in patients undergoing keloid scar revision. Adults 18 years and older with an established diagnosis of keloid scar formation, scheduled to undergo keloid scar revision surgery, and who meet the protocol's inclusion and exclusion criteria are eligible for this study. There will be a minimum of 20 completed subjects with up to 30 enrolled. After keloid revision surgery, subjects will apply product every other day for one month. There will be a total of 5 study visits: Visit 0 (Revision Surgery Date and Start of Treatment); Visit 1 (1 Week Post-Revision); Visit 2 (4 Weeks Post-Revision); Visit 3 (12 Weeks Post Revision); and Visit 4 (24 Weeks Post-Revision and Study Exit). Imaging, Patient and Observer Scar Assessment Scale questionnaires, and Dermatological Life Quality Index Questions will be collected. It is hypothesized that there will be a measurable reduction in the amount (number, size) of keloid formation and/or recurrence at 4, 12, and 24 weeks post revision surgery time points. The change in subjects' quality of life as measured by the the Dermatology Quality of Life Index will also be assessed.
BACKGROUND: Status epilepticus (SE) is a top neurological and medical emergency. Adequate staff knowledge and sufficient hospital resources are mandatory for timely management and better outcomes. This study aims to evaluate Palestinian ER doctors' knowledge and beliefs towards SE and assess the state and availability of hospital resources needed to manage SE appropriately.
METHODS: This cross-sectional study surveyed all ER doctors working in the six governmental hospitals in the Gaza Strip during June 2022. A questionnaire assessed the knowledge and beliefs toward SE and the practice of SE knowledge acquisition. Simultaneous field surveys determined the availability of essential medications and resources at each hospital and doctors' actual awareness about the status of these resources. Linear regression determined predictors of higher knowledge scores.
RESULTS: 137 doctors participated (response rate 81%). Most were males, had graduated within six years of data collection, and 45.3% worked at Shifa Medical Complex. 63.5% of participants recognized the correct operational definition of status epilepticus. 85.4 and 83.9% recognized that it might cause permanent brain damage or death, respectively. Only 10.9% recognized the average mortality rate of a single convulsive SE episode. 44.5% believed that awaiting spontaneous SE resolution is a valid approach to management. Significant defects were noted in the awareness of subclinical SE, including its recognition and prevalence in ciritcally ill patients. Having a higher qualification and graduating from local medical schools predicted higher scores. In field surveys, EEG was unavailable at all hospitals, while CT scans and a neurologist physician were unavailable at two hospitals. IV phenytoin was the only second-line treatment available at all hospitals. IV valproate and levetiracetam were universally unavailable.
CONCLUSIONS: The survey revealed significant defects in Palestinian ER doctors' knowledge and beliefs towards SE. Several hospitals also demonstrated a critical lack of resources to manage this condition appropriately. This should be addressed by the local health authorities to avoid potentially preventable SE-related mortality and morbidity.
Pegloticase (8 mg) intravenous (IV) every two weeks. Methotrexate (15 or 25 mg weekly) SC.
Sodium chloride 9 mg/mL and water for injection s.q. f 1 mL.
In this study, patients with early stage, HER2-negative breast cancer will receive neoadjuvant treatment with ixabepilone and cyclophosphamide given every three weeks for a total of six cycles. Following surgery patients with hormone receptor-positive tumors will receive anti-estrogen treatment. Patients may receive local regional radiation therapy after surgery per institutional guidelines at the investigator's discretion. Baseline tumor tissue and tumor tissue removed at the time of surgery will be tested by Oncotype Detailed Description (DX) assay to determine whether it is predictive of response to this neoadjuvant treatment regimen. This study will be one of the first investigations of the combination of ixabepilone and cyclophosphamide as neoadjuvant treatment for HER2-negative breast cancer. It will examine this treatment regimen for potential advantages gained from substitution of ixabepilone for a taxane and use of non-anthracycline agents.
Protease-activated receptor-2 (PAR2) is a class-A G protein-coupled receptor (GPCR) activated by serine proteases and is expressed by multiple tissues, including the skin. PAR2 is involved in the skin inflammatory response, promoting Th2 inflammation, delaying skin barrier repair, and affecting the differentiation of keratinocytes. It also participates in the transmission of itch and pain sensations in the skin. Increasing evidence indicates that PAR2 plays an important role in the pathogenesis of inflammatory skin diseases such as acne vulgaris, rosacea, psoriasis, and atopic dermatitis. Additional focus will be placed on potential targeted therapies based on PAR2. The Goal of this review is to outline the emerging effects of PAR2 activation in inflammatory skin disease and highlight the promise of PAR2 modulators.